WO2015112705A3 - Therapeutic combinations for treating cancer - Google Patents

Therapeutic combinations for treating cancer Download PDF

Info

Publication number
WO2015112705A3
WO2015112705A3 PCT/US2015/012442 US2015012442W WO2015112705A3 WO 2015112705 A3 WO2015112705 A3 WO 2015112705A3 US 2015012442 W US2015012442 W US 2015012442W WO 2015112705 A3 WO2015112705 A3 WO 2015112705A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating cancer
therapeutic combinations
cancer
nsclc
treating
Prior art date
Application number
PCT/US2015/012442
Other languages
French (fr)
Other versions
WO2015112705A2 (en
Inventor
Andrew D. SIMMMONS
Thomas Christian HARDING
Original Assignee
Clovis Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clovis Oncology, Inc. filed Critical Clovis Oncology, Inc.
Publication of WO2015112705A2 publication Critical patent/WO2015112705A2/en
Publication of WO2015112705A3 publication Critical patent/WO2015112705A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to combination treatment methods for treating cancer, particularly non-small cell lung cancer (NSCLC). More specifically, the invention relates to methods of treating or managing cancer, particularly NSCLC, in a subject, comprising administering an irreversible mutant EGFR inhibitor compound in combination with one or more antineoplastic agents, particularly an Aurora kinase inhibitor.
PCT/US2015/012442 2014-01-24 2015-01-22 Therapeutic combinations for treating cancer WO2015112705A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931285P 2014-01-24 2014-01-24
US61/931,285 2014-01-24

Publications (2)

Publication Number Publication Date
WO2015112705A2 WO2015112705A2 (en) 2015-07-30
WO2015112705A3 true WO2015112705A3 (en) 2015-10-22

Family

ID=53682120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/012442 WO2015112705A2 (en) 2014-01-24 2015-01-22 Therapeutic combinations for treating cancer

Country Status (1)

Country Link
WO (1) WO2015112705A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201726686A (en) * 2015-12-31 2017-08-01 韓美藥品股份有限公司 Crystalline forms of thienopyrimidine compound
BR112018013356A2 (en) 2015-12-31 2018-12-04 Hanmi Pharm Ind Co Ltd hydrochloride salt, crystalline forms of a hydrochloride salt and pharmaceutical composition
WO2017205459A1 (en) 2016-05-26 2017-11-30 Kalyra Pharmaceuticals, Inc. Egfr inhibitor compounds
KR20200132902A (en) * 2018-03-13 2020-11-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Methods of treating cancer with EGFR activating mutations
WO2021244602A1 (en) * 2020-06-05 2021-12-09 Shanghai Lide Biotech Co., Ltd. Human nsclc cell lines and use thereof
WO2022192139A1 (en) * 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281935A1 (en) * 2008-12-12 2011-11-17 Vladimir Ratushny Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer
US20120294867A1 (en) * 2011-05-17 2012-11-22 Boehringer Ingelheim International Gmbh Method for egfr directed combination treatment of cancer
US20140011810A1 (en) * 2009-12-23 2014-01-09 Gatekeeper Pharmaceuticals, Inc. Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110281935A1 (en) * 2008-12-12 2011-11-17 Vladimir Ratushny Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer
US20140011810A1 (en) * 2009-12-23 2014-01-09 Gatekeeper Pharmaceuticals, Inc. Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith
US20120294867A1 (en) * 2011-05-17 2012-11-22 Boehringer Ingelheim International Gmbh Method for egfr directed combination treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WALTER, AO ET AL.: "Discovery Of A Mutant-Selective Covalent Inhibitor Of EGFR That Overcomes T790M-Mediated Resistance In NSCLC.", CANCER DISCOVERY., vol. 3, no. 12, December 2013 (2013-12-01), pages 1404 - 1415, XP055230789, ISSN: 2159-8274 *

Also Published As

Publication number Publication date
WO2015112705A2 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
MX2020012165A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
CA2983481A1 (en) Janus kinase inhibitor
WO2015112705A3 (en) Therapeutic combinations for treating cancer
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12015502042B1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
MX2019008701A (en) Combination therapy involving diaryl macrocyclic compounds.
WO2015184145A8 (en) Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
EA201300810A1 (en) ANTI-TRACT THERAPY USING DOUBLE INHIBITORS KINAZ AURORA / MEK
NI201400095A (en) METHODS FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER USING COMBINED THERAPY OF INHIBITOR TOR KINASE.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MX2016013600A (en) Method of treating lung adenocarcinoma.
WO2016164401A8 (en) Treatment of lung cancer with inhibitors of glutaminase
WO2014140989A3 (en) Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12017500881B1 (en) Aurora a kinase inhibitor
WO2017027359A8 (en) Pyridines and their use in the treatment of cancer
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2016016388A (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds.
WO2017187343A3 (en) Nanoemulsions and methods for cancer therapy
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
MX2017009110A (en) Combination therapy for pulmonary hypertension.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15740712

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15740712

Country of ref document: EP

Kind code of ref document: A2